These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10430827)

  • 1. 'Like a thief in the night': the selectivity of degeneration in Parkinson's disease.
    Saper CB
    Brain; 1999 Aug; 122 ( Pt 8)():1401-2. PubMed ID: 10430827
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K.
    Yamada T; McGeer PL; Baimbridge KG; McGeer EG
    Brain Res; 1990 Sep; 526(2):303-7. PubMed ID: 2257487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter.
    Hartmann A; Hunot S; Hirsch EC
    Exp Neurol; 2003 Dec; 184(2):561-4. PubMed ID: 14769349
    [No Abstract]   [Full Text] [Related]  

  • 5. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1421-36. PubMed ID: 10430829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease.
    Uhl GR
    Ann Neurol; 1998 May; 43(5):555-60. PubMed ID: 9585349
    [No Abstract]   [Full Text] [Related]  

  • 7. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates.
    Collier TJ; Kanaan NM; Kordower JH
    Nat Rev Neurosci; 2011 Jun; 12(6):359-66. PubMed ID: 21587290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The functional anatomy of noradrenergic neurons in Parkinson's disease.
    Soldani P; Fornai F
    Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
    [No Abstract]   [Full Text] [Related]  

  • 10. [Expression of calcium-binding proteins parvalbumin and calbindin in neurons of the neocortex grafts].
    Aleksandrova MA; Girman SV; Revishchin AV
    Dokl Akad Nauk; 1997 Jul; 355(1):130-3. PubMed ID: 9333410
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of Parkinson's disease.
    Hirsch EC; Jenner P; Przedborski S
    Mov Disord; 2013 Jan; 28(1):24-30. PubMed ID: 22927094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein aggregation in Parkinson's disease.
    Gundersen V
    Acta Neurol Scand Suppl; 2010; (190):82-7. PubMed ID: 20586742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy.
    Hardman CD; Halliday GM; McRitchie DA; Morris JG
    J Neuropathol Exp Neurol; 1997 Feb; 56(2):132-42. PubMed ID: 9034366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease.
    Saper CB; Sorrentino DM; German DC; de Lacalle S
    Ann Neurol; 1991 Jun; 29(6):577-84. PubMed ID: 1892359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neural degeneration in Parkinson's disease.
    Riederer P; Reichmann H; Janetzky B; Sian J; Lesch KP; Lange KW; Double KL; Nagatsu T; Gerlach M
    Adv Neurol; 2001; 86():125-36. PubMed ID: 11553969
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulation of calcium homoeostasis in neurons: the role of calcium-binding proteins.
    Miller RJ
    Biochem Soc Trans; 1995 Aug; 23(3):629-32. PubMed ID: 8566431
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular pathways of neurodegeneration in Parkinson's disease.
    Dawson TM; Dawson VL
    Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
    Trojanowski JQ; Goedert M; Iwatsubo T; Lee VM
    Cell Death Differ; 1998 Oct; 5(10):832-7. PubMed ID: 10203692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.